Efficacy and Safety of Dapoxetine for the Treatment of Premature Ejaculation: Integrated Analysis of Results from Five Phase 3 Trials

Journal of Sexual Medicine

Volumn 8, Issue 2, 2011, Pages 524-539

  McMahon, Chris G ^a   Althof, Stanley E ^b   Kaufman, Joel M ^c   Buvat, Jacques ^d   Levine, Stephen B ^e   Aquilina, Joseph W ^f   Tesfaye, Fisseha ^f   Rothman, Margaret ^f   Rivas, David A ^f   Porst, Hartmut ^g  

^a Australian Centre for Sexual Health   (Australia)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Urology Research Options   (United States)

^d CETPARP/Le grand Hunier   (France)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^g Private Urological Practice   (Germany)

Author keywords

Control over Ejaculation; Dapoxetine; Distress; Intravaginal Ejaculatory Latency Time; Premature Ejaculation

Indexed keywords

DAPOXETINE; PLACEBO;

ADULT; AKATHISIA; ARTICLE; BARNES AKATHISIA RATING SCALE; BECK DEPRESSION INVENTORY; CLINICAL GLOBAL IMPRESSION SCALE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; INSOMNIA; INTRAVAGINAL EJACULATORY LATENCY TIME; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD CHANGE; MULTICENTER STUDY; NAUSEA; PARAMETERS OF MEASUREMENT AND ANALYSIS; PATIENT ASSESSMENT; PHASE 3 CLINICAL TRIAL; PREMATURE EJACULATION; PREMATURE EJACULATION PROFILE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; RISK ASSESSMENT; SEXUAL INTERCOURSE; SIDE EFFECT; SOMNOLENCE; SUICIDE;

EID: 79551492867     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.02097.x     Document Type: Article

References (52)

1. Althof SE. Prevalence, characteristics and implications of premature ejaculation/rapid ejaculation. J Urol 2006;175:842-8.
2. Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J. The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: Prevalence, comorbidities, and professional help-seeking. Eur Urol 2007;51:816-24.
3. Rosen RC, Althof S. Impact of premature ejaculation: The psychological, quality of life, and sexual relationship consequences. J Sex Med 2008;5:1296-307.
4. Giuliano F, Patrick DL, Porst H, La Pera G, Kokoszka A, Merchant S, Rothman M, Gagnon D, Polverejan E, for the 3004 study group. Premature ejaculation: Results from a five-country European observational study. Eur Urol 2008;53:1048-57.
5. Patrick DL, Althof SE, Pryor JL, Rosen R, Rowland DL, Ho KF, McNulty P, Rothman M, Jamieson C. Premature ejaculation: An observational study of men and their partners. J Sex Med 2005;2:358-67.
6. Hobbs K, Symonds T, Abraham L, May K, Morris MF. Sexual dysfunction in partners of men with premature ejaculation. Int J Impot Res 2008;20:512-7.
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. text revision. Washington, DC: American Psychiatric Association; 2000.
8. McMahon CG, Althof SE, Waldinger MD, Porst H, Dean J, Sharlip ID, Adaikan PG, Becher E, Broderick GA, Buvat J, Dabees K, Giraldi A, Giuliano F, Hellstrom WJ, Incrocci L, Laan E, Meuleman E, Perelman MA, Rosen RC, Rowland DL, Segraves R. An evidence-based definition of lifelong premature ejaculation: Report of the International Society for Sexual Medicine (ISSM) Ad Hoc Committee for the definition of premature ejaculation. J Sex Med 2008;5:1590-606.
9. World Health Organization. International statistical classification of diseases and related health problems: Tenth revision. Geneva: World Health Organization 1992:355-6.
10. McMahon CG. Clinical trial methodology in premature ejaculation observational, interventional, and treatment preference studies-part II-study design, outcome measures, data analysis, and reporting. J Sex Med 2008;5:1817-33.
11. McMahon C. The etiology and management of premature ejaculation. Nat Clin Pract Urol 2005;2:426-33.
12. Mayo Clinic staff. Men's health: Premature ejaculation. Treatments and drugs. Available at: (accessed March 12, 2010).
13. Morales A, Barada J, Wyllie MG. A review of the current status of topical treatments for premature ejaculation. BJU Int 2007;100:493-501.
14. McCabe MP. Evaluation of a cognitive behavior therapy program for people with sexual dysfunction. J Sex Marital Ther 2001;27:259-71.
15. Abdel-Hamid IA, El Naggar EA, El Gilany AH. Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int J Impot Res 2001;13:41-5.
16. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B. Effect of SSRI antidepressants on ejaculation: A double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol 1998;18:274-81.
17. Safarinejad MR, Hosseini SY. Safety and efficacy of citalopram in the treatment of premature ejaculation: A double-blind placebo-controlled, fixed dose, randomized study. Int J Impot Res 2006;18:164-9.
18. Safarinejad MR. Safety and efficacy of escitalopram in the treatment of premature ejaculation: A double-blind, placebo-controlled, fixed-dose, randomized study. J Clin Psychopharmacol 2007;27:444-50.
19. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000;85:11-28.
20. Modi NB, Dresser MJ, Simon M, Lin D, Desai D, Gupta S. Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol 2006;46:301-9.
21. Buvat J, Tesfaye F, Rothman M, Rivas DA, Giuliano F. Dapoxetine for the treatment of premature ejaculation: Results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol 2009;55:957-68.
22. McMahon C, Kim SW, Park NC, Chang CP, Rivas D, Tesfaye F, Rothman M, Aquilina J. Treatment of premature ejaculation in the Asia-Pacific region: Results from a phase III double-blind, parallel-group study of dapoxetine. J Sex Med 2010;7:256-68.
23. Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJG, Shabsigh R, Miloslavsky M, Kell S, for the Dapoxetine Study Group. Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation: Integrated analysis of two randomized, double-blind, placebo-controlled trials. Lancet 2006;368:929-37.
24. Kaufman JM, Rosen RC, Mudumbi RV, Tesfaye F, Hashmonay R, Rivas D. Treatment benefit of dapoxetine for premature ejaculation: Results from a placebo-controlled phase III trial. BJU Int 2009;103:651-8.
25. Patrick DL, Giuliano F, Ho KF, Gagnon DD, McNulty P, Rothman M. The Premature Ejaculation Profile: Validation of self-reported outcome measures for research and practice. BJU Int 2009;103:358-64.
26. Beck AT, Steer RA, Brown GK. Beck depression inventory manual. 2nd edition. San Antonio, TX: The Psychological Corporation; Harcourt Brace and Company; 1996.
27. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
28. Snaith RP, Harrop FM, Newby DA, Teale C. Grade scores of the montgomery-asberg depression and the clinical anxiety scales. Br J Psychiatry 1986;148:599-601.
29. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-5.
30. Hamilton Anxiety Rating Scale (HAM-A). 2008. Available at: (accessed March 12, 2010).
31. Barnes TR. The Barnes Akathisia Rating Scale-Revisited. J Psychopharmacol 2003;17:365-70.
32. Posner K, Oquendo MA. Suicidality classification project. Available at: (accessed March 12, 2010).
33. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biol Psychiatry 1998;44:77-87.
34. Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH. Geometric mean IELT and premature ejaculation: Appropriate statistics to avoid overestimation of treatment efficacy. J Sex Med 2008;5:492-9.
35. Novaretti JPT, Pompeo ACL, Arap S. Selective serotonin re-uptake inhibitor in the treatment of premature ejaculation. Braz J Urol 2002;28:116-22.
36. Kara H, Aydin S, Yucel M, Agargun MY, Odabas O, Yilmaz Y. The efficacy of fluoxetine in the treatment of premature ejaculation: A double-blind placebo controlled study. J Urol 1996;156:1631-2.
37. Safarinejad MR, Hosseini SY. Safety and efficacy of tramadol in the treatment of premature ejaculation: A double-blind, placebo-controlled, fixed-dose, randomized study. J Clin Psychopharmacol 2006;26:27-31.
38. Safarinejad MR. Safety and efficacy of venlafaxine in the treatment of premature ejaculation: A double-blind, placebo-controlled, fixed-dose, randomised study. Andrologia 2008;40:49-55.
39. Athanasios Z, Polyanthi P, George K. The efficacy of duloxetine in the treatment of premature ejaculation. Int Urol Nephrol 2007;39:115-8.
40. Althof SE, Levine SB, Corty EW, Risen CB, Stern EB, Kurit DM. A double-blind crossover trial of clomipramine for rapid ejaculation in 15 couples. J Clin Psychiatry 1995;56:402-7.
41. Mattos RM, Marmo Lucon A, Srougi M. Tadalafil and fluoxetine in premature ejaculation: Prospective, randomized, double-blind, placebo-controlled study. Urol Int 2008;80:162-5.
42. Waldinger MD, Zwinderman AH, Olivier B. Antidepressants and ejaculation: A double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone. J Clin Psychopharmacol 2001;21:293-7.
43. Waldinger MD, Quinn P, Dilleen M, Mundayat R, Schweitzer DH, Boolell M. A multinational population survey of intravaginal ejaculation latency time. J Sex Med 2005;2:492-7.
44. Waldinger MD, McIntosh J, Schweitzer DH. A five-nation survey to assess the distribution of the intravaginal ejaculatory latency time among the general male population. J Sex Med 2009;6:2888-95.
45. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. Spanish working group for the study of psychotropic-related sexual dysfunction. J Clin Psychiatry 2001;62(3 suppl):10-21.
46. Lane RM. A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management. J Psychopharmacol 1997;11:72-82.
47. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16:356-62.
48. Tamam L, Ozpoyraz N. Selective serotonin reuptake inhibitor discontinuation syndrome: A review. Adv Ther 2002;19:17-26.
49. Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: A literature review. J Clin Psychiatry 1997;58:291-7.
50. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: A comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:85-102.
51. Waldinger MD. Premature ejaculation: Definition and drug treatment. Drugs 2007;67:547-68.
52. Porst H, McMahon CG, Althof SE, Sharlip I, Bull S, Aquilina JW, Tesfaye F, Rivas DA. Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: Integrated analyses of two phase 3 dapoxetine trials. J Sex Med 2010;7:2231-42.